NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) reached the public markets through its merger with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners LLC that completed its initial public offering in 2018. The vehicle targeted the biopharmaceutical sector and ultimately combined with NeuroRx, Inc., a clinical-stage company focused on central nervous system and respiratory drug development, to form the publicly traded NRX Pharmaceuticals. The 10-K filing submitted to the SEC on March 30, 2020 covers annual disclosures from the pre-merger period, when the SPAC was still advancing its search for a target business. Sign up at SpacDesk for full filing history, deal timelines, and analytics on NRXP and hundreds of additional SPAC transactions.